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Abstract 12 
We developed a novel deconvolution method, namely Inference of Cell Types and Deconvolution (ICTD) that 13 
addresses the fundamental issue of identifiability and robustness in current tissue data deconvolution problem. 14 
ICTD provides substantially new capabilities for omics data based characterization of a tissue microenvironment, 15 
including (1) maximizing the resolution in identifying resident cell and sub types that truly exists in a tissue, (2) 16 
identifying the most reliable marker genes for each cell type, which are tissue and data set specific, (3) handling 17 
the stability problem with co-linear cell types, (4) co-deconvoluting with available matched multi-omics data, and 18 
(5) inferring functional variations specific to one or several cell types. ICTD is empowered by (i) rigorously derived19 
mathematical conditions of identifiable cell type and cell type specific functions in tissue transcriptomics data and20 
(ii) a semi supervised approach to maximize the knowledge transfer of cell type and functional marker genes21 
identified in single cell or bulk cell data in the analysis of tissue data, and (iii) a novel unsupervised approach to22 
minimize the bias brought by training data. Application of ICTD on real and single cell simulated tissue data23 
validated that the method has consistently good performance for tissue data coming from different species, tissue24 
microenvironments, and experimental platforms. Other than the new capabilities, ICTD outperformed other state-25 
of-the-art devolution methods on prediction accuracy, the resolution of identifiable cell, detection of unknown sub26 
cell types, and assessment of cell type specific functions. The premise of ICTD also lies in characterizing cell-27 
cell interactions and discovering cell types and prognostic markers that are predictive of clinical outcomes.28 
Introduction 29 
Tissue deconvolution aims to disentangle the cell composition in terms of their relative quantities, based on 30 
which, the cell type specific functions and their cross-talks in the tissue microenvironment could be studied 1 2 3 31 
4 . Existing deconvolution algorithms usually assume the observed expression matrix as a product of a cell type 32 
signature matrix S and proportion matrix P 2 3 4 . Independent training data is usually needed to impose prior on 33 
S via certain information transfer 2 5 6 7 . The recent emergence of single cell RNA-seq (scRNA-seq) allows 34 
researchers to uncover new biological traits in cell populations of bulk tissue8. Regardless, the knowledge 35 
transfer from training single/bulk cell data to target bulk tissue should be carefully handled, as the gene 36 
expression distribution of the two domains could be highly variable, which tend to be oversimplified in current 37 
deconvolution methods 9 . Novel or rare cell subtypes are of great interest to researchers 10. However, current 38 
deconvolution algorithms usually assume a fixed pool of cell types, which clearly is incapable of identifying novel 39 
sub cell types 2 3 4 . Moreover, certain cell types such as immune cells tend to co-infiltrate in a real tissue, 40 
suggesting that the proportions of these cell populations are highly co-linear 11 . As a result, estimating 41 
proportions with plain linear regression model or non-negative factorization would suffer from multi-collinearity, 42 
leading to highly unstable predictions 12 13 . Recent methods such as Cell Population Mapping (CPM) and 43 
CIBERSORTx have been developed to predict cell type specific functions 14 9 . However, they rely on precisely 44 
predicted cell proportions, and matched scRNA-seq profiles of similar tissues, which limited their applications to 45 
a wider extent. It is also noteworthy that none of the existing deconvolution methods is designed to handle highly 46 
varied tissue microenvironments or multi-omics data. Here, we summarize the key challenges of deconvolution 47 
methods as (i) detect the resident (sub) cell types and their true marker genes dependent on the tissue 15 (ii) 48 
handle systematic expression variations from training to target data domain; (iii) deal with the prevalent co-49 
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linearity in the cell type specific expression signatures and cell proportions; (iv) define expression patterns that 50 
represent varied cell type specific functions; (v) enable application to a variety of tissue microenvironment and 51 
multi-omics data types. More detailed discussions and comparisons of the formulations of existing methods are 52 
provided in the Supplementary Notes. 53 
Based on a preliminary evaluation of the variations of known cell type signature genes in a large set of single 54 
and bulk cell data, we first derived mathematical conditions for a cell type to be “identifiable” in a tissue omics 55 
data: (1) the cell type has uniquely expressed genes, the expression values of which over any subset of samples 56 
form a rank-1 matrix (a matrix with matrix rank equals to one), or (2) there are genes expressed by the cell type 57 
and  other cell types satisfy (1), and the expression values contributed by the cell type over any subset of samples 58 
form a rank-1 matrix. And a cell type-specific function is “identifiable” if there are marker genes of the function 59 
forming a rank-1 submatrix in a subset of samples with significant presence of the cell type. These “identifiability” 60 
conditions grant the potential to detect novel cell subtypes or cell functions via the detection of low rank matrices. 61 
Detailed mathematical considerations and derivations were given in Online Methods and Supplementary 62 
Notes. 63 
Based on the rigorously derived mathematical conditions, we developed a semi-supervised method, namely 64 
inference of cell types and deconvolution (ICTD), featured by: (1) a semi-supervised detection of “identifiable” 65 
cell types and marker genes specific to each omics dataset and tissue micro-environment; (2) a novel 66 
nonparametric detection and annotation of cell type signature genes, which is used as information basis to 67 
annotate the identified cell types; (3) a novel constrained non-negative matrix factorization (NMF) method to 68 
decrease the bias caused by knowledge transfer from training data, as well as to effectively handle the co-69 
occurring cells; (4) a robust regression based approach to interactively deconvolute multi-omics data of matched 70 
samples, and (5) a local-low-rank screening approach to identify cell type specific functions, which altogether 71 
offers a systematic solution of the five key challenges. 72 
Results 73 
Our core algorithm ICTD consists of six steps (Fig 1): (1) Compute the relative specificity of all genes for all cell 74 
types in a given microenvironment. A labeling matrix 𝐿M×K  of M  genes and K  selected cell types is first 75 
constructed based on training single or bulk cell transcriptomics data, where 𝐿i,j =
1
𝑙
, 𝑙 = 1,… , 𝐾 − 1, if gene 𝑖 is 76 
significantly expressed in in cell type 𝑗 and its expression is significantly lower than in 𝑙 − 1 other cell types, and 77 
𝐿𝑖,𝑗 = 0 otherwise (Supplementary Table S1). Without loss of generality, we assume that all the M genes are 78 
specific to one or a few cell types, namely,  Σ𝑗𝐿i,j > 0,∀ 𝑖 = 1,… ,𝑀. (2) Detect all gene modules within which the 79 
gene expression vectors are linearly dependent and form rank-1 matrix, and the modules present evidence of 80 
“identifiable” cell types. For each gene module detected on the target tissue expression matrix among the M 81 
genes, if its member genes are all highly expressed in one or several cell types according to the labeling matrix, 82 
the module will be considered as evidence of potential cell type(s) by ICTD. In this step, ICTD can exclude 83 
undesired cell types, such as cancer or other disease cells, from further analysis, by a non-negative projection 84 
of the input data to the complementary of the space spanned by the marker genes of undesired cell types. (3) 85 
Infer the “identifiable” cell types and signature genes. Non-negative linear dependency among the selected 86 
modules is evaluated and each module is annotated by the genes’ significant enrichment to a cell type based on 87 
the labeling matrix. Modules are merged with high inter-dependency, and further filtered such that modules 88 
enriching none of the cell types are removed. The total number of “identifiable” cell types is computed as the 89 
total rank of the expression matrix composed by all genes in the remaining rank-1 modules, the genes in each 90 
module will be considered as markers of the corresponding cell type. (4) Predict cell proportions using 91 
constrained NMF. With the “identifiable” cell types and their marker genes, a constraint matrix CM×K can be 92 
constructed. Specifically, for cell type 𝑘, 𝑘 = 1. . 𝐾  with Mk  marker genes, C(∑ Mk𝑘=1,..,𝐾 )×K[𝑖, 𝑗] = 1, if gene 𝑖  is93 
marker of the cell type 𝑗 , and 0 otherwise. The constraint matrix is then enforced upon the regular NMF 94 
formulation to guarantee similarity of the signature matrix with the constraint matrix, namely, we solve 95 
min
S,P
(‖X − S ∙ P‖𝐹
2 + 𝜆 ∙ trace(ST ∙ (𝟏M𝟏k
T − C))), where 𝟏d denotes an all-1 column vector of length 𝑑. (5) Co-96 
deconvolution of matched multi-omics data. The semi-supervised property of ICTD enable its application to multi-97 
omics data. A robust regression approach is further applied to identify the cell types and samples, in which the 98 
cell proportions inferred from different omics-data are highly consistent. (6) Estimate cell type specific functions. 99 
For each cell type detected, ICTD screens the rank of the expression matrix containing a group of samples which 100 
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are stratified by their cell abundance levels, and pins down marker genes of a varied cell type specific function if 101 
they form at least one distinct dimension.  102 
103 
104 
Figure 1. Analysis pipeline of ICTD. ICTD first constructs labeling matrix to store genes’ relative specificity to different cell 105 
types using bulk or single cell training data (Step 1). Rank-1 modules were detected among the cell type marker genes in 106 
each input omics dataset (Step 2). Similar modules were merged, modules that do not (non-negatively) depend on other 107 
modules are kept, and modules that do not overrepresent any cell type markers are removed. The number of cell types 108 
of the target deconvolution is determined as the total rank of the expression matrix of genes in the remaining modules 109 
(Step 3). A constrained NMF is conducted to regularize the signature matrix 𝑆, such that values in 𝑆 are shrunken towards 110 
0 if the corresponding entries in the constraint matrix is 0. (Step 4). If matched multi-omics data are available, robust 111 
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regression among cell proportions inferred from different omics data set is performed to remove outlier samples (Step 5, 112 
optional).  Marker genes of cell type specific functions are further identified by looking for local low rank submatrices in 113 
sample groups stratified by different level of the cell proportion (Step 6).  114 
The core algorithms for each step are described in the Online Methods. Detailed algorithms, data used for 115 
method validation, and model comparisons with other methods, are provided in the Supplementary Notes and 116 
Methods. Below we present the application of ICTD on simulated bulk data using single cell RNA-seq data (Fig. 117 
2) and real tissue data (Fig. 3). We demonstrated (1) the ability of ICTD to identify both known and novel (sub) 118 
cell types with high accuracy, (2) the overall competitive performance of ICTD in analyzing data of different tissue 119 
microenvironment and experimental platforms, (3) the robustness of ICTD in cases where cell types have highly 120 
co-linear proportions, (4) ICTD’s capability in interactive deconvolution of matched multi-omics data, (5) inference 121 
of cell type specific functions, and (6) explorative findings derived by correlating ICTD predicted cell and 122 
functional levels with other omics, imaging and clinical data. 123 
Validation on single cell simulated bulk tissue data 124 
We benchmarked ICTD on predicting the types of resident cells and their relative proportions against three state-125 
of-art deconvolution methods, namely CIBERSORT, TIMER, and EPIC (Online Methods), using single cell 126 
simulated bulk tissue datasets. The bulk tissue datasets were simulated by RNA-seq data of single cells or single  127 
nucleus from different tissue microenvironments, including five from human solid cancer (namely, breast, colon, 128 
head and neck, lung, and melanoma), five from human central nervous system (namely glioblastoma, 129 
oligodendroglioma, astrocytoma and two normal brain), three from human immune system (monocyte and 130 
dendritic cell, lymphoid, and myeloid progenitor cells), and one from mouse melanoma. On all five human solid 131 
cancer microenvironment, all mixing cell types were detected as “identifiable” by ICTD. In addition, ICTD 132 
achieved significantly higher accuracy in predicting total B-, T-, mast, fibroblast, endothelial cells and 133 
macrophage proportions comparing to other methods. On 23 out of the 25 cells type in the simulated bulk cancer 134 
datasets, ICTD predicted relative proportions achieved higher than 0.95 Pearson correlation coefficient (PCC) 135 
with true proportions, while the average PCC is 0.86, 0.63 and 0.52 for EPIC, TIMER and CIBERSORT, 136 
respectively (Fig 2a). On the five human brain microenvironments, ICTD successfully detected astrocyte, 137 
oligodendrocyte and progenitors, exhibitory and inhibitory neuron, microglial and Schwann cells as identifiable 138 
cell types, all with at least 0.9 PCC with true proportions (Fig 2b). Similarly, ICTD also accurately identified sub 139 
ell types from the mixture of multiple classes of monocyte and dendritic cells, human lymphoid and myeloid 140 
progenitors, and the immune and stromal cells in mouse melanoma microenvironment, with reliable prediction 141 
of proportions (Fig 2b).  142 
Novel cell types. A unique feature of ICTD is its capability to automatically detect cell and sub cell types along 143 
with cell marker genes for effective cell (sub)type annotation. Our analysis on simulated cancer tissue data 144 
suggested that each of the rank-1 module corresponds to one cell or sub-cell type (Supplementary Fig S1). On 145 
the simulated human solid cancer datasets, ICTD was able to identify subtypes of immune/stromal cells, 146 
including CD4+ and CD8+ T cells, novel subtypes of fibroblast and myeloid cells. The sub cell type markers were 147 
further validated by the tSNE visualization, where the expression level of each marker set turns out to be specific 148 
to the associated cell types or subtypes (Supplementary Fig S2). As illustrated in Fig 2c, among the three 149 
fibroblast rank-1 modules identified by ICTD, one clearly corresponds to the general fibroblast (with COL1A1 150 
expression) type, and the other two correspond to two fibroblast subtypes (with COL8A1 or SERPINF1 151 
expression) in the simulated human melanoma data. We confirmed all the rank-1 modules identified by ICTD 152 
from all the single cell simulated tissue data are specifically expressed in only one cell type, suggesting the high 153 
specificity of ICTD in identifying true cell types. 154 
Variability of cell types and their marker genes. It is noteworthy that the number of identifiable cell types could 155 
vary through disease contexts and data sets. Comparing to the fixed cell types assumed in most of the 156 
deconvolution methods, the number of cell types identified by ICTD highly matches the number of mixing cell 157 
types in each single cell simulated tissue data set (Fig 2d). We further investigated the level of variation for cell 158 
type markers through different disease contexts and data set. As shown in Fig 2e, there is a strong disease 159 
context specificity of T cell markers: only four T cell markers were shared by all the five cancer data sets, and 160 
19 T cell markers were shared in four out of the five data sets. We observed on average 93.75%, 90.36% and 161 
83.33% of the T cell markers utilized in CIBERSORT, TIMER and EPIC are specific to only three or less cancer 162 
types and only 65.21%, 69.57% and 13.04% of the common cell type marker genes were included in their 163 
signature matrix. Similar patterns are also seen for B and fibroblast cells (Supplementary Fig S3). In contrast, 164 
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ICTD considers the variations in both the identifiable cell types and cell type markers in different tissues and 165 
datasets, resulting in a better prediction accuracy throughout different scenarios (Fig 2e-f). An explanation score 166 
(ES) is defined for each marker gene to evaluate the goodness of fitting of the gene’s expression by the predicted 167 
proportions of the cell types expressing the gene (Online Methods). High ES scores of the marker genes for 168 
one cell type is a necessary condition for the high prediction accuracy and specificity of the marker genes. We 169 
observed strong positive correlations between the ES scores and prediction accuracy using ICTD and EPIC, as 170 
these two methods rely on cell type uniquely expressed genes. Similarly, for CIBERSORT and TIMER, positive 171 
associations were also observed (Fig 2g). Analysis of six major immune and stromal cell types in five simulated 172 
bulk cancer data sets suggested that in general, when ES is below 0.8, the prediction accuracy is lower than 0.8; 173 
on the other hand, when ES is above 0.9, the prediction accuracy tends to higher than 0.9 (Fig 2g). We observed 174 
the ES of all the cell type specific markers identified by ICTD on the simulated cancer tissue data are all above 175 
0.95. It is noteworthy ES can partially evaluate the performance of a deconvolution method without knowing true 176 
cell proportions. 177 
 178 
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Figure 2. Validation of ICTD by using single cell simulated bulk tissue data. (a) PCC between true and predicted proportion 179 
of six cell types by ICTD, EPIC, TIMER and CIBERSORT, in the bulk tissue data simulated using scRNA-seq data collected 180 
from Melanoma (MLN), Head and Neck Cancer (HNC), Colorectal Cancer (CRC), Breast Cancer (BRC), and Lung Cancer (LNC). 181 
(b) PCC between true and predicted proportion of cell types and subtypes identified by ICTD in the bulk tissue data182 
simulated by scRNA-seq data of myeloid and dendritic cell mixture (BLD), lymphoid and myeloid progenitor mixture (LMP),183 
mouse melanoma (MMLN), normal brain cells nucleic sequencing generated in this study (BR-IU), glioblastoma (GBM),184 
human normal brain (HBS), oligodendroglioma (ODG), and astrocytoma (ATC). Detailed cell type codes are given in185 
Supplementary Note. (c) t-SNE plot of the marker genes of fibroblast subtypes in MLN scRNA-seq data, which were186 
identified by ICTD from simulated human melanoma tissue data. In each panel, darker color denotes higher expression of187 
the gene in a cell. (d) Consistency of the number of ICTD identified cell types and the matrix rank of the expression profile188 
of the marker genes of identified cell types, i.e. the number of identifiable cell types, in each simulated tissue data. (e)189 
Distribution of the true T cell marker genes identified in the five cancer data and their overlap with the actually used T cell190 
signature genes in CIBERSORT, TIMER and EPIC. Each bar and number represent the number of genes specifically expressed191 
by T cells in each of five cancer types, which is labeled in the dot plot on the bottom. The pie charts illustrate the proportion192 
of the T cell marker genes used by ICTD (data adaptive) and CIBERSORT, TIMER and EPIC (held fixed). (f) Re-evaluation of193 
robustness of cell type specific markers used by each method. The circle size represents the ratio of true marker genes194 
among all genes used as marker genes for each cell type (row) for each method (column).  The color represents the E-195 
score level. The two columns of each method show the results of simulated MLN (left) and HNC (right) tissue data. The196 
plots of the other three cancer types were shown in Supplementary Fig S6. (g) Dependency between explanation score (x-197 
axis) and prediction accuracy (y-axis) of the cell type proportions given by the four methods. (h) PCC (y-axis) between true198 
and predicted T and B cell proportions on simulated data with different level of T and B cell co-infiltration (x-axis). (i-j)199 
prediction of varied T cell cytotoxicity level in simulated HNC data. From left to right, the four plots illustrate the kernel200 
function used for local low rank screening, co-expression network of T cell and cytotoxic marker genes, heatmap of201 
correlations between T cell and cytotoxic marker genes, and p values of the expression matrix rank of the T cell and202 
cytotoxic marker genes, in the samples of low T cell infiltration (i) and high T cell infiltration level (j).203 
Cell type co-linearity. ICTD also demonstrated its superiority in handling co-linearity of cell proportions, caused 204 
by cells’ functional dependencies. Our preliminary analysis on TCGA data suggested correlation among the 205 
immune and stromal cells to be as high as 0.94 (Supplementary Notes). We simulated batches of bulk tissue 206 
samples in each of which the cell proportions are intentionally set to have different levels of correlations to mimic 207 
the dependencies of different cell types in cancer microenvironment (Online Methods). Not surprisingly, while 208 
performance of regression based methods dropped significantly when co-linearity level was high, ICTD achieved 209 
high robustness and prediction accuracy at different levels of co-linearity. This owes to the data-adaptive 210 
selection of cell type specific markers and constrained NMF formulation adopted by ICTD. The four methods’ 211 
prediction accuracy of B and T cells across different co-linearity levels in simulated human melanoma tissue data 212 
is shown in Fig 2h. In addition, significant correlations among ES, prediction accuracy, and co-linearity of cell 213 
proportions were identified (Supplementary Fig S4). 214 
Cell type specific functions. ICTD can identify varied function of a certain cell type using a local low rank 215 
identification approach 16 . In the human head and neck cancer data, we identified the expression level of 216 
cytotoxic gene in the CD8+ T cells vary considerably in patient stratifications of different T cell abundances, 217 
suggesting mixed T cell exhaustion levels (Supplementary Notes). To evaluate the capability of ICTD in 218 
identifying varied T cell cytotoxicity level, we simulated bulk tissue data with different proportion and cytotoxicity 219 
level of T cells (Online Methods). ICTD conducted a local low rank screening with a kernel function along 220 
samples ordered by predicted T cell proportions. Our analysis clearly identified the linear space spanned by the 221 
T cell and cytotoxicity marker genes switches from rank-1 to rank-2 throughout the samples with low to high T 222 
cell levels, suggesting the identifiability of the varied cytotoxic level in the samples of high T cell infiltrations (Fig 223 
2i-j). On average, correlation level of 0.86 between the true cytotoxicity level per unit T cell and the prediction 224 
made by ICTD was observed (Supplementary Fig S5). 225 
Implications from real tissue data 226 
We then applied ICTD on a collection of human cancer, normal, blood and inflammatory tissue (CNBI) data, 227 
including 28 cancer and 11 normal tissue types from TCGA, 17 colorectal cancer, 7 triple negative breast cancer, 228 
7 blood tissue, and 11 human inflammatory disease data sets from GEO (Supplementary Table S3). We 229 
identified rank-1 markers of B, T, dendritic, general myeloid, macrophage, monocytes, neutrophil, fibroblast, 230 
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endothelial and adipocyte cell and their sub cell types in each dataset (Fig 3a and Supplementary Fig S7). A 231 
strong association between the number of identified cell types and the total rank of the matrix of marker genes 232 
was observed (Fig 3b). It is noteworthy that the types of resident cells most variable across different cancer 233 
types are the subtypes of adipocytes, fibroblast, and myeloid cells, which seem to be most prevalent in breast, 234 
colorectal, lung, pancreatic and stomach cancers, commonly known to have considerable stromal components. 235 
The complete set of cell types and their marker genes identified in each data set were summarized in 236 
Supplementary Table S4. In the TCGA datasets, 21 commonly “identifiable” cell and subtype types have been 237 
observed in more than 10 cancer types, including CD19/CD22 expressing regulatory-like B cell and 238 
CD79A/CD79B expressing activated B cell; total, CD8+, and CD4+ T cell; Neurexin and Caytaxin expressing 239 
Neuron cell; myofibroblast-like cell; Collagen 1/3/5, Collagen 4/15/18, Collagen 6, and Non-collagen expressing 240 
Fibroblast; Endothelial cell; MHC class II antigen presenting cell; MHC class I, pro-inflammatory cytokine 241 
releasing, chemokine and cytokine releasing Myeloid cells; complement pathway activated Macrophage and 242 
Monocytes; granulocytes; and adipocytes (Fig 3c).  243 
 244 
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Figure 3. Application of ICTD on real bulk tissue transcriptomics data. (a) The number of identifiable cell types (colored 245 
bar) and the matrix rank (grey bar) of their marker genes identified by ICTD through all the TCGA cancer data; (b) Scatter 246 
plot of the number of identifiable cell types (y-axis) and the matrix rank (x-axis) of their marker genes identified by ICTD 247 
through all the analyzed data. (c) Network of the marker genes of the commonly identified cell (sub) types in the TCGA 248 
data. An edge between two genes means the two genes are both identified as markers of one cell type in more than 10 249 
analyzed TCGA data. (d) E-score of the T cell marker genes identified by ICTD and those used by EPIC, TIMER and 250 
CIBERSORT in TCGA data. E-score of other cell types are given in Supplementary Fig S11. (e) Correlation (y-axis) between 251 
the imaging data derived tumor infiltrated lymphocyte level and T cell proportion predicted by the four methods (x-axis) 252 
in 11 TCGA cancer. (f) Scatter plot of the T cell proportions predicted by TCGA BRCA RNA-seq and ATAC-seq data. Samples 253 
with highest consistency identified by the robust regression were pink colored. The bar plots represent the correlations 254 
of the proportions inferred by the RNA-Seq vs ATAC-Seq (or RNA-Seq vs imaging) in all the samples (PCC=0.62, or 0.23) 255 
and the most consistent samples (PCC=0.96, or 0.64). (g) Consistency of ICTD predicted (x-axis) and FACS measured (y-256 
axis) cell proportions of four hematopoietic cell types. (h) Evaluation of T cell markers identified in CNBI data. In the 257 
heatmap, each row is the commonly identified T cell markers and each column is one data set. Color in the heatmap 258 
represents the E-score of each gene in each data set. Statistics of other cell types are given in Supplementary Fig S12. (i) 259 
Clustering of datasets from different microenvironment from different platforms based on a distance measure of the 260 
marker gene expression profiles of identifiable cell types (see Online Methods). This is to show the relative impact of 261 
technological platforms and tissue microenvironment on the variability of gene markers expressions. (j) Co-expression 262 
between T cell, CD8+ T cell, cytotoxic function, CD4+ T cell and T-reg marker genes in the samples with high T cell 263 
infiltration in TCGA COAD data. (k) Correlation between fibroblast cell expressing genes and T cell infiltration level 264 
conditional on the fibroblast cell level in 15 cancer types. (l) Survival curves of the TCGA COAD patients with low, medium 265 
and high T cell infiltration, and the high T cell infiltration patients with low and high cytotoxicity functions predicted by 266 
ICTD. (m) Variation of T cell infiltration level in response (R) and non-response (NR) patients in three independent 267 
checkpoint inhibitor treated clinical data. (n) Variation of T cell relative cytotoxic level in response (R) and non-response 268 
(NR) patients in five independent checkpoint inhibitor treated clinical data. LUAD, LUSC and MLN* represents different 269 
sets of lung adenocarcinoma, lung squamous cell carcinoma and melanoma. 270 
We confirmed markers of each commonly identifiable cell types in cancer microenvironment do have significant 271 
overlaps with the immune and stromal cell markers identified in normal microenvironment, suggesting these 272 
marker genes truly belong to immune and stromal cells rather than cancer cells (Supplementary Table S5). On 273 
average, the ICTD marker genes of each cell type have ES higher than 0.9, while the ES scores of the signature 274 
genes used by CIBERSORT, TIMER and EPIC are 0.22, 0.39 and 0.26, respectively. Fig 3d illustrate the ES of 275 
T cell (sub)type markers of the four methods. The level of tumor infiltrated lymphocytes (TIL) in 12 TCGA cancer 276 
types have been previously assessed by imaging data 17 . On average, the correlation between imaging predicted 277 
TIL and ICTD predicted T cell level is 0.4, comparing to 0.14, 0.2, and -0.11 with CIBERORT, TIMER, and EPIC 278 
predicted T cell level (Fig 3e). For other cell types, with a lack of ground truth, we rely on evaluating the ES 279 
scores of 3,552 known immune and stromal cells marker genes. It turns out that ICTD-predicted cell proportions 280 
achieved on average 0.56 R2 value in explaining the 3,552 known immune and stromal cells marker genes, while 281 
the R2 is 0.2, 0.24, and 0.18 for CIBERSORT, TIMER, and EPIC (Supplementary Table S6).  282 
ICTD enables interactive deconvolution of matched multi-omics data. We co-deconvoluted the RNA-seq, ATAC-283 
seq and DNA methylation data of five TCGA cancer types with available data (Online Methods). On average, 284 
more than 70% of the cell types identified from RNA-seq data were also identified in ATAC-seq or methylation 285 
data, including adipocytes, B cell, CD4+ and CD8+ T cell, macrophage, fibroblast, endothelial and dendritic cells 286 
(Supplementary Table S7). The correlations between cell proportions inferred from different data types are higher 287 
than 0.6. Fig 3f illustrated the strong consistency between the T cell proportion inferred from TCGA BRCA RNA-288 
seq and ATAC-seq data. It is noteworthy the samples used in multi-omics experiments were from different parts 289 
of a tumor tissue, and some are less representative of the whole tumor tissue. ICTD utilizes a robust regression 290 
approach to remove such samples with inconsistent cell proportions inferred from the multiple data sources. As 291 
a result, the correlation between RNA-seq and imaging inferred T cell proportion was increased from 0.23 to 292 
0.64, wherein the imaging based proportion is deemed as a reliable reference here. This suggests the interactive 293 
co-deconvolution of multi-omics data has the potential to increase the robustness of the prediction. 294 
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Application of ICTD on 7 human normal brain, 5 neuro-degenerative disease and 4 brain cancer data sets 295 
identified 23 common cell types in central nervous system, including two astrocyte, three general glial,  two 296 
oligodendrocyte, oligodendrocyte progenitor, exhibitory and inhibitory neuron, MHC class I and II antigen 297 
presenting cells, general myeloid, macrophage, neutrophil and stromal like microglial cells, one endothelial, one 298 
epithelial, three ependymal, and one collagen expressing stromal like cell types (Supplementary Fig S8).  299 
To experimentally validate ICTD in identifying rare sub cell types and predicting cell proportions in complex tissue 300 
system, we generated an RNA-seq data set of 12 mouse bone marrow tissue samples each with flow cytometry 301 
(FACS) measured cell numbers (see details in Supplementary Notes). ICTD successfully identified all the four 302 
hematopoietic cell types measured by FACS, namely hematopoietic stem cell, general myeloid progenitor, 303 
mature myeloid cell and pre-B cell, and achieved correlations of 0.92, 0.86, 0.8 and 0.97 between predicted and 304 
FACS measured cell proportions. Complete statistics including labeling matrix of mouse hematopoietic cell types, 305 
cell type specific markers identified by ICTD, cell proportions predicted by ICTD and measured by FACS were 306 
given in Fig 3g, Supplementary Table S8 and Supplementary Fig S9. 307 
ICTD considers the variability of resident cell types and their marker genes across tissue microenvironments and 308 
technology platforms. Fig 3h illustrate the ES of T cell expressing genes in different CNBI data sets, suggesting 309 
a significant variation of the T cell markers in the microenvironment of different cancer, inflammatory disease 310 
and blood tissue, as well as under different experimental platforms 18 19. To further investigate how the data set 311 
specific makers vary by disease/tissue micro-environments or experimental platforms, we further computed the 312 
averaged Jaccard distance between the marker genes of same cell types identified in any two CNBI or single 313 
cell simulated bulk datasets (Supplementary Methods). As illustrated in Fig 3i, the cell type marker genes vary 314 
drastically between cancer, normal inflammatory and blood tissues. Three distinct clusters were observed (1) 315 
TCGA cancer and other cancer, (2) single cell simulated cancer, and (3) TCGA normal and other inflammatory 316 
disease, and blood tissue. Among the cancer data, TCGA and other RNA-seq based cancer data sets is well 317 
separated from scRNA-seq simulated cancer data and the Microarray cancer data sets, and the later one is 318 
further divided into two sub-clusters containing independent CRC and TNBC data sets. Similarly, the TCGA 319 
RNA-seq and microarray data of normal, inflammatory conditions, and blood tissue form three distinct sub-320 
clusters. Among the microarray data of chronic inflammatory conditions, the disease of digestive system and 321 
airway and skin tissues from two sub-clusters.  322 
ICTD detected general T cell, fibroblast, and myeloid cells in all 28 analyzed TCGA cancer types, while the CD8+ 323 
T, non-collagen extracellular component expressing fibroblast, and oxidative stress producing myeloid cells were 324 
identified as distinct cell types in only 10, 12, and 15 cancer types, respectively. We found that the markers of 325 
these functional sub cell types are detected as cell type specific functions instead of a cell type in some cancer 326 
types by the local low rank screening function. For the 19 cancer types where CD8+ T cell is not identified as a 327 
cell type, CD8+ T cell markers were treated as one T cell specific function in 15 cancer types, while in 4 cancer 328 
types, high concordance is observed between total T cell and CD8+T cell markers in all the samples, making the 329 
CD8+ T subtype not differentiable from the general T cell. Fig 3j illustrated the marker genes of general T, CD8+ 330 
T, CD4+ T and T-reg cells form a distinct rank-4 submatrix in samples with high T cell infiltration, while the genes 331 
were less distinguishable in the complete TCGA COAD data (Supplementary Fig 10). This suggests the “locality” 332 
of finding identifiable cell types and functions, and hence it is necessary to implement a local low rank module 333 
detection approach. Similar locality was also observed for the marker genes of non-collagen expressing 334 
fibroblast and NADPH oxidase expressing myeloid cells in certain TCGA cancer types and other analyzed CRC 335 
and TNBC data sets (Supplementary Fig S10). We also conducted comprehensive screening to identify unknown 336 
immune/stromal cell type specific functional genes (Online Methods). 84 major functional modules were 337 
identified as common cell type specific functions in TCGA data (Supplementary Notes). 338 
Cell-cell interaction. The prediction of cell proportions and functions by ICTD makes it possible to computationally 339 
characterize cell-cell interactions. We observed co-infiltrations among immune and stromal cell types with PCC 340 
in the range of -0.2-0.94 in all the analyzed TCGA cancer data (Supplementary Table S9). More importantly, the 341 
functional promotion or inhibition of cell type A to cell type B could now be examined by the correlations between 342 
the abundance level of A and the activity level of the function in B, conditional on the predicted proportion of B. 343 
We found seven genes expressed by fibroblast cells with significant negative conditional correlation with T cell 344 
infiltration in at least 10 out of 15 cancer types with high level of stromal cells (p<0.01) (Fig 3k). The seven genes 345 
execute functions related to the modification and synthesis of collagen and extracellular polysaccharide, 346 
suggesting a possible role of the dysregulated extracellular matrix composition in directing T cell infiltration. 347 
Similarly, the interactions of functions in two cell types can be computed by the correlation of the activity levels 348 
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of the two functions conditional to their proportions. We identified a low conditional correlation among CD8 T cell 349 
markers such as CD8A/CD8B and cytotoxic genes, and a high conditional correlation among general T, CD8+ 350 
T, and cytotoxic genes in 4 cancer types, suggesting possibly perturbed cytotoxicity of T cells in the first 19 351 
cancer types, namely T cell exhaustion. We also observed a significant negative correlation (p <0.01) between 352 
the NADPH oxidase and T cell cytotoxicity levels conditional to the total myeloid and T cell in 11 out of the 25 353 
TCGA cancer types (Supplementary Table S10). This is consistent with previous observation that NADPH 354 
oxidases produce reactive oxygen species (ROS) on the surface of myeloid-derived suppressor cells that 355 
suppress the cytotoxic function of T cells 20. 356 
Clinical implications. ICTD enables investigation of the impact on clinical prognosis by microenvironment. We 357 
conducted association analysis between the predicted cell proportions and varied functions with patient’s overall 358 
survival in TCGA data, as well as patients’ response in five clinical trial data with immune checkpoint inhibitor 359 
treatment (Supplementary Methods). We identified significant associations of patients’ overall survival with T 360 
cell infiltration and relative cytotoxicity levels in 12 and 7 TCGA cancer types, respectively. More interestingly, in 361 
colorectal and ovarian cancer, we observed that patients with moderate level of T cell infiltration have the best 362 
overall survival comparing to the patients with high and low T cell levels (Fig 3l). We define the T cell’s relative 363 
cytotoxicity (RC) level as the predicted cytotoxic function. level divided by the predicted total T cell level in each 364 
sample and observed patients with higher RC have significantly better overall survival. This clearly suggests the 365 
existence of T cell exhaustion and its association with poor prognosis. On the five clinical trial data, we noticed 366 
that patients with high T cell infiltration have better response to the treatment (Fig 3m), which is consistent with 367 
previously reported 21. Moreover, the level of T cell cytotoxicity was observed to vary significantly in four datasets 368 
of melanoma, lung adenocarcinoma and lung squamous carcinoma. We observed the patients with lower RC 369 
tend to have better clinical response (Fig 3n), possibly due to more PD-1/PD-L1-mediated immuno-suppression 370 
in these tumors. It is noteworthy that association between T cell infiltration and patients’ clinical outcome, and 371 
the identifiability of varied cytotoxic function show a high consistency between TCGA and the clinical trial data 372 
(Supplementary Table S10). 373 
Discussion 374 
Our semi-supervised deconvolution method ICTD brought up a novel notion called “identifiability” of a cell type 375 
and cell type specific function, which was mathematically rigorously defined. By adaptively defining detectable 376 
cell types and selecting cell type markers based on the input data resolution, ICTD highly reduces the estimation 377 
bias, and also enables detection of novel cell (sub) types, and cell type functional activities. These features are 378 
particularly favorable when the goal is to computationally characterize the cell-cell interactions in large-scale 379 
tissue transcriptomic profiles. It is noteworthy that the “transcriptionally identifiable” cell types differ from those 380 
defined by cell differentiation lineage: some cell types on the lineage map may not be identifiable, while an 381 
“identifiable” cell type can be a certain cell or cell subtype, or the total of several cell types on the lineage map 382 
that express same gene markers. We believe the liberty of ICTD in its deconvoluted cell types makes it entirely 383 
data-driven, less biased to the training data, and it thus grants more sensible findings for downstream correlation 384 
analysis with other clinical and biological features.  385 
ICTD is flexible in utilizing different types of training data to construct the labeling matrix, and we noticed using 386 
scRNA-seq profiles of cells from the real microenvironment of a certain cancer type, we are able to derive more 387 
tissue specific cell type markers than using microarray expression profiles of primary cells collected from healthy 388 
donors (Supplementary Notes). It is also worthy of mention that since ICTD is not fully supervised, we suggest 389 
at least 10 samples is needed for the method to work. While the method has increased type II error when the 390 
sample size is small, the identified rank-1 gene modules can be informative in guiding the flexible selection of 391 
cell type signature genes. Based on this, our ICTD R package was integrated with a regression based approach 392 
specifically for small sized samples with data-guided gene markers. When multi-omics data is available, we 393 
showed that co-deconvolution of matched multi-omics data could improve the prediction robustness, by 394 
excluding certain “outlier” samples with unstably predicted proportions using robust regression, and this function 395 
is available in the ICTD R package. The R package and web server version of ICTD are available at 396 
https://github.com/changwn/ICTD and https://shiny.ph.iu.edu/ICTD/. 397 
Application of ICTD on TCGA pan-cancer data identified variations of T cell marker, cytotoxic marker and T cell 398 
exhaustion level, association between fibroblast expressing genes and T cell infiltration level, and association 399 
between ROS produced by myeloid cell and T cell cytotoxic level in different cancer types, suggesting the 400 
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capacity of ICTD in providing a comprehensive evaluation of tissue specific cell types, cell type specific function, 401 
and cell-cell interactions. Nevertheless, the sensitivity of detecting cell type varied function can be largely 402 
improved if more prior knowledge of functional marker genes is available. And additionally, more novel cell type 403 
functions can be predicted if the rank-1 module detection approach could be optimized such that certain modules 404 
may exist with respect to only a subset of samples, considering the prevalence of disease heterogeneity and 405 
subtype specificity. In other words, co-expression modules local to subset of samples may be desirable in 406 
revealing more cell type functions.  407 
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Online Methods 408 
Single cell, bulk cell and tissue transcriptomics data sets used in this study 409 
We collected bulk cell data of 11 types in human blood, inflammatory and cancer tissue microenvironment, 8 410 
types in human central nervous system, all generated by Affymetrix UA133 plus 2.0 Array; and 13 types in mouse 411 
inflammatory and tissue microenvironment, generated by Affymetrix Mouse Genome 430 2.0 Array. Detailed cell 412 
types include: human stromal and immune cells: fibroblast (34, 387), adipocytes (3, 26), endothelial cell (29, 413 
606), B cell (20, 404), CD4+ T cell (23, 443), CD8+ T cell (9, 130), natural killer cell (9, 141), dendritic cell (32, 414 
410), monocytes (22, 477), macrophages (21, 277), and neutrophil (10, 257); human central nervous system: 415 
neuron (16, 243), Schwann cell (2, 14), astrocyte (10, 57), ependymal cell (1, 39), oligodendrocyte (4, 30), and 416 
microglial cells (43,754), endothelial (29, 606), and stromal-like cell (34, 387); mouse stromal and immune cells: 417 
fibroblast (28, 277), adipocytes (3, 63), myocytes (myocyte), endothelial cell (10, 56), B cell  (6, 31), CD4+ T cell 418 
(6, 80), CD8+ T cell (3, 34), natural killer cell (7, 35), dendritic cell (12, 84), monocytes (10, 46), macrophages 419 
(8, 102), neutrophils (11, 36), and mast cell (3, 31). The two numbers in the parenthesis indicate the number of 420 
datasets and samples of each cell type. We believe these cell types, together with tissue primary cells can cover 421 
major cell populations in the microenvironment of solid cancer, inflammatory disease, central nervous and 422 
hematopoietic system.  2854 samples of cancer cell line, human and mouse tissue index, and other cancer and 423 
normal tissue data were utilized as background to exclude the genes expressed by cancer or tissue primary cells. 424 
The method was validated on single cell simulated bulk data. 13 single cell RNA-seq data sets generated by 425 
either C1/SMART-seq2 or 10x Genomics pipelines are used, and the cells are collected from (1) the TME of 426 
human solid cancer melanoma (8, 4486), breast (7, 535), colorectal (8, 375), head and neck (9, 5902), and lung 427 
cancer (8, 6630), (2) human glioma (5, 751), oligodendroglioma (7, 2728), and astrocytoma (7, 5171), (3) one 428 
public  (8, 420) and one in-house (5, 1239) human normal brain sets, (4) human myeloid cell lineage and 429 
lymphoid cell lineage (3, 318) and monocyte/dendritic cell populations (4, 700), and (5) the TME of mouse 430 
melanoma (9, 2903). The two numbers indicate the number of cell types and cells of each data set. 431 
We applied ICTD on real bulk tissue transcriptomic data of (1) 28 TCGA cancer types, (2) 11 TCGA normal 432 
tissue data, (3) 17 independent microarray data sets of colorectal cancer measured by different platforms; (4) 433 
metabric and 6 other triple negative breast cancer data sets; (5) 7 blood tissue RNA-seq and microarray data; 434 
(6) 11 human inflammatory disease data sets generated by Affymetrix UA133 plus 2.0 Array, and (7) 7 human 435 
normal brain, 5 neuro-degenerative disease and 4 brain cancer types. Detailed information of the bulk cell, 436 
scRNA-seq and bulk tissue data were provided in Supplementary Table S3. The sample information and 437 
selection, downloading and processing procedures of the public data, and sample and sequencing information 438 
of the inhouse generated data were given in Supplementary Notes. 439 
Preliminary derivation of the mathematical conditions of “Identifiable” cell types and cell type specific functions 440 
As detailed in Supplementary Notes, we analyzed the following characteristics of the cell type signature genes 441 
in the scRNA-seq and bulk tissue data of different disease context, experimental platforms and batches: (1) the 442 
consistency of cell type uniquely expressed genes were evaluated by their averaged expression level in different 443 
cell types of different scRNA-seq data sets; (2) inter- and intra- sample variations of cell type signature genes 444 
were characterized by the “drop-out” rates and multimodality of each gene’s expression profile in the scRNA-445 
seq data of different samples; (3) matrix rank and expression scale of cell type uniquely expressed genes in bulk 446 
tissue data were evaluated by using BCV based rank test and Kolmogorov Smirnov (KS) test, and (4) immune 447 
and stromal cell co-infiltrations in cancer and inflammatory tissues were further assessed by using the averaged 448 
co-expression correlations among a small number of known cell type uniquely expressed genes. 449 
Our evaluation suggested that NMF solution may not be unique if the used marker gene set are expressed by 450 
more than one cell type due to the prevalent co-linearity of cell proportions (Supplementary Notes). Hence only 451 
the cell type with uniquely expressed genes are transcriptomically “identifiable”, and the markers genes should 452 
also be stably expressed through cells of the same type so that its tissue level expression can reflect the cell’s 453 
population in the tissue. Specifically, if gene 𝑖 is uniquely and stably expressed in cell type 𝑘, its gene expression 454 
can be expressed as X𝑖,∙ = 𝑆𝑖
𝑘 ∙ P𝑘,∙ + 𝑒, where 𝑆𝑖
𝑘 is the unit expression of 𝑖 in 𝑘, and 𝑃𝑘,∙ is the relative proportion 455 
of cell type 𝑘 across all the samples. This shows that genes uniquely expressed by a cell type forms a (matrix) 456 
rank-1 submatrix, which form a necessary condition of “transcriptomically identifiable” cell type. On the other 457 
hand, a significant rank-1 structure of the expression profile of multiple genes X𝑖,∙, 𝑖 = 1…𝑚 suggests that these 458 
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genes are highly possibly expressed by a dominating cell type in the current tissue microenvironment or the 459 
genes are with similar expression pattern in several cell types. 460 
Noting cell type specific functional activities, such as the T cell cytotoxicity, are highly varied through different 461 
patients, it is not feasible to use constant gene expressions level to characterize their activities. Denote the 462 
averaged level of a functional gene 𝑖 in cell type k in the sample j as 𝑆𝑖,𝑗
𝑘 , our evaluation suggested that the 463 
function is identifiable only if there exists a group of marker genes 𝑖 = 1…𝐾 satisfy 𝑆𝑖,𝑗
𝑘 ∙ P𝑘,𝑗, 𝑗 = 1…𝑁 form a 464 
rank-1 matrix. Specifically, the cell type specific functional genes should share the same rank-1 space with the 465 
cell type markers if there is no variation while the functional genes can be identified as the markers of a cell type 466 
if 𝑆𝑖,𝑗
𝑘  varied in all samples. If only a subset of samples has the functional variation, the low rank structure of the 467 
functional genes will be absorbed by the cell type markers and diminish on the co-expression network of all the 468 
samples. For such a case, the linear base of the varied function can be distinguished when the computation was 469 
limited to the samples with the functional variation, i.e. a local low rank identification method is needed (See 470 
more discussions in Supplementary Notes).  471 
A modified Bi-cross validation (BCV) based test of matrix rank 472 
Bi-cross validation (BCV) has been developed to estimate the matrix rank for singular value decomposition (SVD) 473 
and Non-negative Matrix Factorization (NMF), which requires a prefixed low dimension 𝐾 and two low rank 474 
matrices for the approximation 𝑋𝑀×𝑁 = 𝑊𝑀×𝐾 ∙ 𝐻𝐾×𝑁.. The error distribution of gene expression data is usually non-475 
identical/independent, majorly because a gene’s expression can be affected by its major transcriptional 476 
regulators, other biological pathways and experimental bias. Hence undesired biological characteristics and 477 
experimental bias may form significant dimensions in a gene expression data 22. In sight of this, we developed a 478 
modified BCV rank test (Algorithm 1) to minimize the effect of the non-i.i.d errors in assessing the matrix rank 479 
of a gene expression data.  480 
Algorithm 1: Modified Bi-cross validation matrix rank test 481 
𝐹𝑜𝑟 𝑟 = 1…𝑅 482 
 𝑆𝑎𝑚𝑝𝑙𝑒 row index set 𝐼𝑟 = {i1, i2, … , i[𝑀
𝐶
]
|𝑖𝑝 ∈ {1…𝑀}} , 𝐼?̅? = {1…𝑀}\𝐼 483 
 𝑆𝑎𝑚𝑝𝑙𝑒 column index set 𝐽𝑟 = {j1, j2, … , j[𝑁
𝐶
]
|𝑗𝑝 ∈ {1…𝑁}} , 𝐽?̅? = {1…𝑁}\𝐽 484 
 𝑆𝑝𝑙𝑖𝑡 𝑋 into for submatrix |
𝐴𝑟 𝐵𝑟
𝐶𝑟 𝐷𝑟
| , 𝑤ℎ𝑒𝑟𝑒 𝐴𝑟 = 𝑋[𝐼𝑟 , 𝐽𝑟], 𝐵𝑟 = 𝑋[𝐼𝑟, 𝐽?̅?],  485 
 𝐶𝑟 = 𝑋[𝐼?̅?, 𝐽𝑟], 𝐷𝑟 = 𝑋[𝐼?̅?, 𝐽?̅?] 486 




















 (∗)   488 
Rankx ← 0 489 







 𝐷𝑜 t test between {BCV(𝑘, 𝑟)|𝑟 = 1…𝑅} and {𝐵𝐶𝑉(𝑘 + 1, 𝑟)|𝑟 = 1…𝑅} 491 
 𝑖𝑓 (p. value < 0.01 & mean (BCV(𝑘 + 1, 𝑟)) − mean (BCV(𝑘, 𝑟)) < msp) 492 
  Rankx ← 𝑘 + 1 493 
𝑅𝑒𝑡𝑢𝑟𝑛 Rankx 494 
(∗) Denote the SVD of a matrix 𝐷 as 𝐷 = 𝑈𝛴𝑉′, and Moore–Penrose inverse of 𝐷  495 




+ ≥  496 
𝜎2
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𝑖=1 𝑢𝑖 497 
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ICTD Step 1: Construction of labeling matrix to represent TME specific cell type marker genes 498 
A labeling matrix 𝐿𝑀×𝐾 was first constructed to represent the genes that are overly expressed in a certain cell 499 
type, where M is the number of genes and K is the number of cell types, 𝐿𝑖,𝑗 =
1
𝑅
 stands for the gene 𝐺𝑖′𝑠500 
expression in cell type 𝐶𝑗 is the Rth highest among its expression in all the cells, and 𝐿𝑖,𝑗 = 0 stands for 𝐺𝑖 is not 501 
a significant signature of cell type 𝐶𝑗. Two different approaches were developed to construct the labeling matrix 502 
by using scRNA-seq or bulk cell data: 503 
(1) scRNA-seq data:504 
For a scRNA-seq data set with annotated cell labels of 𝐾 cell types and a given gene 𝑔, denote the expression 505 
profile of 𝑔 in cell type k as 𝒙𝑔,∙
𝑘 ,  its mean as 𝑥𝑔
𝑘 = 𝑚𝑒𝑎𝑛(𝒙𝑔,∙
𝑘 ), and the Z score of 𝑥𝑔
𝑘 as 𝑧𝑔
𝑘. The cell type order506 
vector 𝒐 was further computed, where 𝒐𝑗 = 𝑘, if the jth largest value of 𝑥𝑔
𝑘 happens to be of cell type k. Then for507 
cell type 𝒐1 to 𝒐𝐾, the labeling matrix was built by 508 
𝐿𝑔,𝑧𝑘 =
{










,   𝑖𝑓 𝒙𝑔,∙
𝒐𝑘 < 𝒙𝑔,∙
𝒐𝑝−1  𝑎𝑛𝑑 𝒙𝑔,∙
𝒐𝑘 ≮ 𝒙𝑔,∙
𝒐𝑝 , 𝑧𝑔
𝑘 ≥ −1.96, 1 ≤ 𝑝 ≤ 𝑘 − 1
509 
, where  𝒙𝑔,∙
𝒐𝑖 < 𝒙𝑔,∙
𝒐𝑗
 denotes 𝑔 is significant over expressed in cell type 𝒐𝑗 compare to cell type 𝒐𝑖, which is tested 510 
by using MAST 23. 511 
(2) bulk cell data:512 
We applied a non-parametric random walk based approach to identify if a gene has higher expression in certain 513 
cell types comparing to others, i.e. a signature gene of the cell types, by using the training data set composed 514 
by a large independent data sets of the cell types. ICTD enables the user to select the cell types specific to a 515 
tissue microenvironment. For examples, bulk cell data of normal breast cell, breast cancer cell lines and breast 516 
cancer tissue samples were selected as background to train the marker genes of immune and stromal cells for 517 
analyzing breast cancer tissue data. The labeling matrix used in this paper were computed by using human 518 
CCLE cell line, human body index and more than 20 human cancer tissue data as the background data. Batch 519 
effect of the training data of each cell type were first removed by using COMBAT 24 and the expression profile of 520 
each sample was further normalized by its mean. 521 
Denote the combined expression matrix containing M genes for N samples of K cell types, and for each cell type, 522 
we first calculated the expected frequency of the cell type, i.e. dividing the total number of samples for the cell 523 
type (𝑁𝑘 , 𝑘 = 1,… , 𝐾) by the total number of samples N, denoted by 𝐸𝑖 = 𝑁𝑘/𝑁 , 𝑖 = 1,… , 𝐾. For a given gene 𝑔 , 524 
denote 𝒙𝑔,∙ and 𝒙𝑔,∙
𝑘  as its expression profile of all cell types and cell type 𝑘. We order the corresponding cell type525 
labels of these samples based on the expression value from large to small, denoted by vector 𝒛, where 𝒛𝒋 = 𝑘, 526 
if the jth largest expression value in 𝒙𝑔,∙ happens to be of cell type k. Denote 𝑶𝑘 as the cumulative frequency of 527 






, 𝑗 = 1,… ,𝑁 529 
, where 𝛿𝑧𝑚=𝑘 is the indicating function for 𝑧𝑚 = 𝑘. A discrepancy score vector 𝒅  between the observed and530 
expected cell type frequency was further defined as  531 




, 𝑗 = 1,… ,𝑁 532 
, where 𝒅 is a non-negative vector of length N, and it attains a minimum value of zero at N. The larger the 533 
maximum value d suggests the expression values are more enriched in certain cell types than the others. Denote 534 
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𝑚 as the index of the maximum of 𝑑, i.e. 𝑑𝑚 = max (𝑑𝑗), and the cell type frequency at the best discrepancy as 535 
𝑒𝑘
𝑚 = 𝑂𝑚𝑘 − 𝐸𝑘, the cell types were further ordered by 𝑒𝑘
𝑚 from large to small and denoted as 𝒐, where 𝒐𝑗 = 𝑘 if 536 
the jth largest value of 𝑒𝑘





0 , 𝑖𝑓 𝑒𝑘






𝑚 > 0 
1
𝑝
,   𝑖𝑓 𝒙𝑔,∙
𝒐𝑘 < 𝒙𝑔,∙
𝒐𝑝−1  𝑎𝑛𝑑 𝒙𝑔,∙
𝒐𝑘 ≮ 𝒙𝑔,∙
𝒐𝑝 , 𝑒𝑘
𝑚 > 0 , 1 ≤ 𝑝 ≤ 𝑘 − 1
, where  𝒙𝑔,∙
𝒐𝑖 < 𝒙𝑔,∙
𝒐𝑗
 denotes 𝑔  is significant 538 
over expressed in cell type 𝒐𝑗 compare to cell type 𝒐𝑖, which is tested by Mann Whitney test. 539 
Exclusion of the expression of undesired cells 540 
ICTD can eliminate the expression signal from undesired cell types to excluder those cells from further analysis. 541 
To do this, ICTD first identifies gene co-expression modules from the decentralized expression matrix of their 542 
marker genes by using WGCNA and computes the first row base of each module by using SVD 25. Then for each 543 
gene that is positively co-expressed with one or several module(s) of the undesired cell type, its expression are 544 
further projected to the complementary space spanned by the first row base of each of such modules (s). Denote 545 
a decentralized tissue data as X, the data of pseudo-code of exclusion of the expression of undesired cells are 546 
given below:  547 
Algorithm 2: Remove the low rank space of undesired cell types 548 
𝑀𝑜𝑑𝑢𝑙𝑒𝑠𝐶  ← 𝑊𝐺𝐶𝑁𝐴(𝑋𝐶) 549 
𝑓𝑜𝑟 𝑖 𝑖𝑛 𝑀𝑜𝑑𝑢𝑙𝑒𝑠𝐶 550 
 𝑈𝑖Σ𝑖𝑉𝑖
𝑇 = 𝑆𝑉𝐷(𝑋𝑖)  551 
𝑅𝐵𝑐[𝑖, ] ← 𝑉𝑖
𝑇[, 1] 552 
𝑓𝑜𝑟 𝑒𝑎𝑐ℎ 𝑔𝑒𝑛𝑒 𝑖𝑛 𝑋 553 
 𝑓𝑜𝑟 𝑘 𝑖𝑛 1: 𝐾 554 
  𝑖𝑓(max (𝑐𝑜𝑟(𝑅𝐵𝑐 , 𝑋𝑔𝑒𝑛𝑒𝑠)) > 0) 555 
   𝑖 ← argmax
𝑖
(𝑐𝑜𝑟(𝑅𝐵𝑐[𝑖, ], 𝑋𝑔𝑒𝑛𝑒𝑠)) 556 




2  557 
𝑟𝑒𝑡𝑢𝑟𝑛(𝑋)  558 
In this paper, we first identified 1089 cancer cell genes, as evidenced by their consistent up-regulation in 11 559 
cancer types of TCGA data and significant expression in CCLE cell line data (Supplementary Table S10). 560 
Differential gene expression analysis was conduct by using Mann-Whitney test with FDR<0.05 as the significant 561 
cutoff and significant expression in cancer cell line data is determined by log(FPKM)>2. In the analysis of one 562 
specific cancer type, gene co-expression modules of the cancer genes were first identified. The linear space 563 
spanned by the modules were further excluded by the complementary space projection. Our analysis on single 564 
cell simulated and real bulk tissue data validated that such an elimination procedure can largely remove the 565 
expression of the genes stably expressed in cancer cells while retaining the low rank structure of the gene 566 
expressions from other cells (See Supplementary Notes). 567 
ICTD Step 2: Identification of rank-1 modules 568 
Highly co-expressed modules were identified using our in-house method, namely MRHCA 26 27. More details 569 
about the MRHCA based module identification and its rationality in our case are given in Supplementary 570 
Methods. 571 
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The BCV test described in Algorithm 1 is further applied to find the modules of rank-1, which possibly 572 
correspond to marker genes of identifiable cell types. The matrix rank of a module centered by a cell type 573 
uniquely expressed genes always increases with the module size, due to the genes less co-expressed with the 574 
hub may be expressed by other cell types. In this paper, we selected the modules of with hub significance p<1e-575 
3, average co-expression correlation>0.8, rank=1 (p<1e-3) and with at least seven genes, as possible markers 576 
of identifiable cell types. 577 
ICTD Step 3: Determine the number and select Rank-1 modules of “identifiable” cell types 578 
After identifying all sets of rank-1 marker genes, ICTD further determines the number of identifiable cell types, 579 
eliminates redundant and insignificant cell type marker genes, annotates each set of marker genes with a most 580 
likely cell type by using the labeling matrix, and build a marker gene – cell type representing matrix for the 581 
downstream deconvolution analysis. 582 
Denote a rank-1 marker set 𝐺𝑖 = {𝑔1, … , 𝑔𝑛𝑖} and labeling matrix  𝐿𝑀×𝐾, we first compute 𝑆𝑖 = {𝑠𝑖,1, … , 𝑠𝑖,𝐾}, where 583 
𝑠𝑖,𝑘 = ∑ 𝐿𝑔𝑗,𝑘
𝑛𝑖
𝑗=1  representing the enrichment level of 𝐺𝑖  to the genes top expressed in cell type k. The 584 
significance level of 𝑠𝑖,𝑘,  𝑝𝑠𝑖,𝑘, is assessed by a permutation test, and 𝐺𝑖 is annotated as cell type with the minimal 585 
𝑝𝑠𝑖,𝑘 if min(𝐹𝐷𝑅(𝑝𝑠𝑖,𝑘)) < 𝐶𝑢𝑡𝑜𝑓𝑓𝐶𝐸𝑆. In this study, 𝐶𝑢𝑡𝑜𝑓𝑓𝐶𝐸𝑆 is selected as 0.01. The rank-1 markers annotated 586 
without a significant cell type annotation are excluded from further analysis. It is noteworthy that a larger 587 
𝐶𝑢𝑡𝑜𝑓𝑓𝐶𝐸𝑆 can be selected for identification of possible unknown cell types.  588 
Rather than predefining the cell types, ICTD determines the cell types that are “identifiable”. In some 589 
circumstance, the proportion of the cell type with a lower resolution is a non-negative linear sum of the proportion 590 
of several cell types with higher resolutions, such as the myeloid cell proportion equals to the sum of macrophage 591 
and neutrophils when these two cell types dominate the myeloid cell populations in the tissue 28. This linear 592 
dependency may correspond to a linear dependency between the row base of marker genes of cell types of 593 
different resolutions, which may result in number of identifiable cell types exceeding the rank of the linear space 594 
generated by the identified rank-1 markers. 595 
To determine the number of identifiable cell types covered by the rank-1 marker genes, ICTD first construct a 596 
tree structure to represent the linear dependency among the identified rank-1 marker sets. A rank-1 marker set 597 
is considered as a root node if its row base can be non-negatively fitted by the row bases of other nodes with 598 
𝑅𝟐 > 𝐶𝑢𝑡𝑜𝑓𝑓𝑅2. In this study, 𝐶𝑢𝑡𝑜𝑓𝑓𝑅2 = 0.9 is selected. The rank-1 marker sets fitting each other with 𝑅
𝟐 >599 
𝐶𝑢𝑡𝑜𝑓𝑓𝑅2 are merged together. All the root rank-1 marker sets are considered as markers of “identifiable” cell 600 
types and excluded from the further analysis. ICTD further computes the rank of the expression matrix of all the 601 
non-root rank-1 maker genes. Denoting the number of non-root rank-1 maker sets and their total rank as 𝑃 and 602 
?̂?. The total number of “identifiable” cell types among the non-root rank-1 marker sets is determined as ?̂?. 603 
A marker gene – cell type representation matrix is further computed for the downstream NMF analysis. Denote 604 
a selected rank-1 marker set as 𝐺𝑖 = {𝑔1, … , 𝑔𝑛𝑖}, 𝑖 = 1…𝑃, its gene expression profile as 𝑋𝐺𝑖, and ot SVD as  605 
𝑋𝐺𝑖 = 𝑈𝑖Σ𝑖𝑉𝑖





, i.e. the averaged R square of the genes’ 606 
expression fitted by their first row base. The marker gene – cell type representation matrix C is constructed by 607 
Algorithm 3: 608 
Algorithm 3: Construction of representation matrix 609 
𝑓𝑜𝑟 𝑖 𝑖𝑛 1…𝑃 610 
𝐶𝑜𝑚𝑝𝑢𝑡𝑒 𝑡ℎ𝑒 𝑆𝑉𝐷 𝑜𝑓 𝑋𝐺𝑖  𝑎𝑠 𝑈𝑖Σ𝑖𝑉𝑖
𝑡 611 
 𝐶𝑜𝑛𝑑𝑢𝑐𝑡 𝑎 ℎ𝑖𝑒𝑟𝑎𝑐ℎ𝑖𝑐𝑎𝑙 𝑐𝑙𝑢𝑠𝑡𝑒𝑟𝑖𝑛𝑔 𝑜𝑓 𝐺𝑖  𝑖𝑛 𝑡𝑜 ?̂? 𝑐𝑙𝑢𝑠𝑡𝑒𝑟𝑠 𝐶𝑗, 𝑖 =612 
1… ?̂?, 𝑏𝑦 𝑢𝑠𝑖𝑛𝑔 𝑒𝑢𝑐𝑙𝑖𝑒𝑎𝑛 𝑑𝑖𝑠𝑡𝑎𝑛𝑐𝑒 𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝑉𝑖[, 1] 613 
𝑓𝑜𝑟 𝑗 𝑖𝑛 1… ?̂? 614 
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𝑆𝑒𝑙𝑒𝑐𝑡  𝑟𝑎𝑛𝑘 1 𝑚𝑎𝑟𝑘𝑒𝑟 𝑠𝑒𝑡 𝐺𝑘𝑗  𝑏𝑦 argmax
𝑗𝑘
(




|𝐺𝑗𝑘 ∈ 𝐶𝑗) 615 
 𝐶∑ 𝑛𝑗𝑘𝑗=1…?̂? ×?̂?
[𝑖, 𝑗] = {
0, 𝑖𝑓 𝑔𝑒𝑛𝑒 𝑖 ∉ 𝐺𝑘𝑗




This step assigns marker genes of identifiable cell types that highly determines the prediction accuracy of the 618 
deconvolution analysis. ICTD also includes three other options in constructing marker genes and C matrix of 619 
identifiable cell types. The computational details and performance comparison of these methods were given in 620 
Supplementary Methods. 621 
ICTD Step 4: Constrained Non-negative Matrix Factorization 622 
With the NMF constraint matrix CSX×K
NMF, each of the K cell type is assigned with at least one cell type uniquely 623 
expressed gene (see derivations in method), hence the constraint NMF problem XM×N = SM×K ∙ PK×N, S[I, k] ≥624 
0, P[k, j] ≥ 0, S[I, k] = 0 𝑖𝑓 CSNMF[I, k] = 0 does have a unique solution 29. The rationale here is that the analysis 625 
only focuses on cell types with uniquely expressed markers that form rank-1 structure, and the analysis is robust 626 
to collinearity of cell proportions due to the uniqueness of solution. Specifically, for the 𝑝 th disconnected 627 
subgraph with Mp genes, rank= Kp, and constraint matrix C𝑀×K, the NMF of X𝑀×N = S𝑀×K ∙ PK×N is solved by 628 
min
S,P
(‖X𝑀×N − S𝑀×K ∙ PK×N‖𝐹
2 + 𝜆 ∙ tr(S𝑀×K
T ∙ (1 − C𝑀×K))), where  S𝑀×K and P𝑀×K  are the predicted signature and 629 
proportion of K cell types. Variables with fitted S that are highly varied from C are further removed. Detailed 630 
solution of the constrained NMF problem was given in Supplementary Methods. It is noteworthy when 𝜆 →  ∞, 631 
𝑃𝑖,𝑗 is the first row base of the SVD of 𝐷𝑖𝑎𝑔(𝐶∙,𝑗) ∙ 𝑋, where 𝐷𝑖𝑎𝑔(𝐶∙,𝑗) is the diagonal matrix generated by 𝐶∙,𝑗. In 632 
this study, 𝜆 was selected based the best prediction accuracy trained on single cell simulated bulk data.  633 
ICTD Step 5: Co-deconvolution of matched multi-omics data 634 
Multi-omics, including epigenetic and chromatin profiles, provide equally important characterization of tissue 635 
compositions as transcriptomic profiles. When multiple omics data are available for the same tissues, it is 636 
reasonable to assume that cell relative proportions deduced from each of the omics profile should be strongly 637 
associated. Based on this, co-deconvolution of matched multi-omics data could be used to cross-validate and 638 
robustify the proportion predictions, as detailed in Algorithm 4: 639 
Algorithm 4: Co-deconvolution of matched multi-omics data  640 
Input:  641 
𝑈(0) = ∅, denoting the set of outlier samples. 642 
For 𝑖 = 1…𝑁𝑖𝑡𝑒𝑟 643 
 Run deconvolution on each of omic profile 𝑙 where only samples not in 𝑈(𝑖−1) are used, denoted the 644 
predicted proportion matrix as 𝑃(𝑖),𝑙, 𝑙 = 1,… , 𝐿, of dimension 𝐾 × 𝑁𝑖, where 𝐾 is the total number of cell types, and 645 
𝑁𝑖 the total number of tissues of the current run;  646 
 Perform robust mixture regression using robust trimmed likelihood estimation (TLE) approach, between 647 
the 𝑟1th row of 𝑃
(𝑖),𝑙1 and 𝑟2th row of 𝑃
(𝑖),𝑙2 648 
 Collect all the outlier samples based on the robust TLE approach for all the runs, and denote the union 649 
set of outlier samples as 𝑈(𝑖) 650 
 Repeat 1-3, and stop if 𝑈(𝑖) = ∅ 651 
ICTD Step 6: Conditional local low rank test of cell type varied function 652 
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Identifiable cell type specific function is defined by a group of genes that form a local rank-1 structure conditional 653 
on the estimated proportion of the cell type. A kernal function based local low rank structure screening method 654 
is developed for identification of such local rank-1 structures. Denote 𝑃𝑘 = {𝑝1
𝑘 , 𝑝2
𝑘 , … , 𝑝𝑛
𝑘} as predicted proportion 655 
of cell type k through the n samples and 𝑃(𝑘) = {𝑝𝑘(1), … , 𝑝𝑘(𝑛)} as sorted 𝑃𝑘 with an increasing order, GIk as the 656 
rank-1 marker genes of cell type k,  and GF𝑘 is a gene set containing possible marker genes of a varied function 657 
of k, the level of functional activity and its associated marker genes can be identified by Algorithm 5:  658 
Algorithm 5: BCV screening of a local low rank structure 659 
For a given data 𝑋 and cell proportion 𝑃𝑘 = {𝑝1
𝑘 , 𝑝2
𝑘 , … , 𝑝𝑛
𝑘} 660 
 𝑆𝑜𝑟𝑡 𝑃(𝑘) by increasing order: 𝑃(𝑘) = {𝑝𝑘(1), … , 𝑝𝑘(𝑛)} 661 
 Reorder the samples in 𝑋 into 𝑋0 𝑏𝑦 𝑡ℎ𝑒 𝑜𝑟𝑑𝑒𝑟 𝑜𝑓 𝑃(𝑘) 662 
For 𝑖 = 1…𝑁 663 
Do BCV test of 𝑋𝑖 ≜ 𝑋
0[(GIk , GFk), ] ∙ 𝑑𝑖𝑎𝑔(𝐾𝑖) (∗) 664 
  pij = FDR correted p value of the rank j of Xi 665 
If ∃ i∗ and j > 1, 666 
s. t.  pij < 0.05 for all i ≥ i
∗ and pij ≥ 0.05 for all i < i
∗ 667 
 → GFk  contains marker genes of a varied function   668 
Identify gene froming  the rank 1 matrices in X[GFk , (i
∗…N)] 669 
(∗) 𝐾𝑖 𝑖𝑠 𝑎 nonnegative kernal function centered at 𝑖: 670 
𝐾𝑖(z) = {
0      , 𝑖𝑓 |𝑧 − 𝑖| ≥ 𝐶1
|𝑧−𝑖|−𝐶2
𝐶1−𝐶2
, 𝑖𝑓 𝐶1 < |𝑧 − 𝑖| < 𝐶2
1       , 𝑖𝑓 |𝑧 − 𝑖| ≤ 𝐶2
, 𝐶2 < 𝐶1, z = 1. . 𝑁 671 
The idea of this algorithm is that the genes of a cell type specific function may form additional ranks in the 672 
samples with high proportion of the cells, which can be identified by the BCV test when only looking at those 673 
samples. The kernel function is to smooth the inter-sample variation in cell proportions (see more details in 674 
Supplementary Methods).  675 
In this paper, GF𝑘 is selected for each cell type k by the genes annotated as top expressed by cell type 𝑘 in the 676 
labeling matrix and with more than 0.8 co-expression correlation with the cell type 𝑘’s proportion. ICTD enables 677 
users to predefine GF𝑘 and select proportion of cell type 𝑘 for a specified analysis, such as using known markers 678 
for prediction of T cell cytotoxicity 30. The functional activity level of each set of gene markers are then predicted 679 
by its first row base in the samples i ≥ i∗ by SVD. Averaged activity level per cell is further estimated by dividing 680 
the predicted functional activity level by the predicted cell type proportion. 681 
Single cell simulated Bulk Tissue data 682 
Cell types in each scRNA-seq data were labeled by the cell clusters provided in the original works or by using 683 
Seurat pipeline with default parameters. Detailed information of the scRNA-seq data and cell type annotation is 684 
given in Supplementary Table S3 and Notes. For each data set, we simulate bulk tissue data with three steps: 685 
(1) randomly generate the proportion of each cell type, called true proportion in this paper, that follows a Dirichlet 686 
distribution, (2) enforce a certain co-infiltration level of two selected cell types, and (3) draw cells randomly from 687 
the cell pool with replacement according to the cell type proportion, and sum up the expression values of all cells 688 
to produce a pseudo bulk tissue data. More details are provided in Algorithm 6: 689 
Algorithm 6: simulate bulk data using single cell 690 
Input: single cell gene expression matrix 𝑆𝑚×𝑛; cell type label vector 𝒍; patient number 𝑝; 𝑡𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑁.  691 
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(optional) 𝐶𝑜𝐹 ∈ {0, 1}; 𝐶𝑜𝑟𝑟 ∈ (0, 1]; 𝑟𝑜𝑤1, 𝑟𝑜𝑤2. 692 
1. Find the cell type number 𝑘 from 𝒍.693 
2. Generate 𝐷𝑘×𝑝, s. t. 𝐝:,i ~𝐃𝐢𝐫𝐢𝐜𝐡𝐥𝐞𝐭(𝜶), 𝑖 = 1,… , 𝑝;  𝜶 = (𝛼1, … , 𝛼𝑘)~𝑼(0,1).694 
3. If 𝐶𝑜𝐹 is TURE go to step 4, else go to step 7.695 
4. 𝑣1, 𝑣2 ←  𝐷𝑖𝑗, 𝑖 ∈ {𝑟𝑜𝑤1, 𝑟𝑜𝑤2}, 𝑗 ∈ {1,… , 𝑝}.696 
5. Generate 𝑢1, 𝑢2, s. t. |𝑐𝑜𝑟(𝑢1, 𝑢2) − 𝑥| ≤ 0.05.697 
6. 𝑣1 ← 𝑢1, 𝑣2 ← 𝑢2.698 
7. For 𝑖 = 1,… , 𝑝; 𝑗 = 1,… , 𝑘:699 
𝑖) 𝒔𝒄𝑖,𝑗 ∼ 𝑆𝑎𝑚𝑝𝑙𝑒 𝐷𝑗,𝑖 ⋅ 𝑁 cells from the pool of cell type 𝑗 with replacement ;700 
𝑖𝑖) 𝐵:,𝑖 =
∑ 𝑆:,𝑡𝑡∈𝒔𝒄𝑖,𝑗  
𝑙𝑒𝑛𝑔𝑡ℎ(𝒔𝒄𝑖,𝑗)
701 
8. Return 𝐵𝑚×𝑝 , 𝐷𝑘×𝑝.702 
, in which: 703 
𝐶𝑜𝑟𝑟 is the coinfiltration level parameter if 𝐶𝑜𝐹 is TRUE; 704 
𝐶𝑜𝐹 is the coinfiltration flag to indicate whether adding dependency to two cell types or not; 705 
𝑟𝑜𝑤1, 𝑟𝑜𝑤2 are the cell type location that indicate two selected cell types adding 𝐶𝑜𝑟𝑟 dependency; 706 
𝒔𝒄𝑖,𝑗 𝑖 ∈ {1,… , 𝑝}, 𝑗 ∈ {1,… , 𝑘} is the selected single cells sampling randomly from the cell pool with replacement; 707 
𝐵𝑚×𝑝 is the simulated bulk tissue expression value matrix;708 
𝐷𝑘×𝑝 is the true proportion matrix.709 
710 
The Dirichlet distribution matrix was generated with R package “DirichletReg” (version 3.5.3). In order to evaluate 711 
the robustness of the deconvolution method while co-infiltration exists, we add different levels of co-infiltrations 712 
in our simulated bulk data to four pairs of cells that are commonly known to co-infiltrate in cancer tissue, namely, 713 
B/T cell, T/NK cell, Fibroblast/Endothelial cell, and B/Dendritic cell. (Supplementary Figure S13). For a robust 714 
method evaluation, five replicates were generated in the simulation of each data set and at each co-infiltration 715 
parameter.  716 
717 
Explanation Score to evaluate the performance of our deconvolution method 718 
We assessed the methods’ performance by the correlation between predicted and known proportion of each cell 719 
type in simulated data, which is inapplicable in the real tissue data. Thus, we developed  720 
An explanation score (ES) was developed to evaluate the goodness that each marker gene’s expression is fitted 721 
by the predicted cell proportions: 722 
















𝑥 ≥ 0724 
where 𝑥𝑗
∗ is the observed expression of marker gene 𝑥 in sample 𝑗, 𝑥𝑗 is the 𝑥’s expression level in 𝑗 predicted725 
by a non-negative regression model of the predicted proportion 𝑝𝑗
𝑘 , 𝑘 = 1…𝑘𝑥 of 𝑘𝑥 cell types that express 𝑥,726 
and 𝛽𝑘
𝑥 are parameters. Intuitively, with correctly selected marker genes, the marker gene’s expression can be 727 
well explained by the predicted proportions of the cell types that express the gene.  Hence, a high ES score is a 728 
necessary but not sufficient condition for correctly selected marker genes and predicted cell proportion. 729 
730 
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